Richard Yee, MD
Ophthalmology · Bellaire, TXNPI 1205817764
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $164,050 of the $194,572 with a category attached, or 84.3%. Bausch & Lomb Americas Inc. accounts for 97.7% of it on its own, with 18 other manufacturers making up the rest. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $505.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$190K
- AbbVie$1K
- Mallinckrodt Hospital Products Inc.$825
- Amgen$475
- Shire North American Group Inc$293
- Bausch & Lomb, A Division Of Bausch Health US, LLC$282
- plus $1K from 13 others
Across 2 payments — averaging $35,599 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch & Lomb Americas Inc.$60K
- Novartis$11K
What the payments were for
- Speaking & faculty fees$164,05084%
- Travel & lodging$21,58211%
- Food & beverage$8,7404%
- Education$2000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 234 | $190,053 |
| AbbVie(2 entities) | 51 | $1,344 |
| Mallinckrodt Hospital Products Inc. | 26 | $825 |
| Amgen(2 entities) | 15 | $475 |
| Shire North American Group Inc | 6 | $293 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $282 |
| Novartis | 14 | $265 |
| Biotissue Holdings Inc. | 3 | $182 |
| Alcon | 4 | $178 |
| Dompe US, Inc. | 8 | $171 |
| Sight Sciences, Inc. | 2 | $161 |
| Sun Pharmaceutical Industries Inc. | 6 | $113 |
| Aerie Pharmaceuticals, Inc. | 3 | $67 |
| Thea Pharma Inc. | 1 | $57 |
| Akorn, Inc. | 2 | $32 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$184,942
- XIIDRA$134,317
- BLINK NUTRITEARS$850
- DURYSTA$328
- ACTHAR$247
- VYZULTA$200
- TEARCARE SYSTEM$143
- Rocklatan$125
- Rhopressa$125
- VUITY$125
- Prokera$124
- AmnioGraft$124
- enVista MX60 IOL$121
- TEPEZZA$102
How this compares
$194,572 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 42 | $34,574 |
| XiidraLifitegrast | 22 | $25,944 |
| Cyclosporine | 28 | $23,668 |
| RestasisCyclosporine | 17 | $19,241 |
| RhopressaNetarsudil Mesylate | 54 | $16,744 |
| Travoprost | 30 | $8,275 |
| TyrvayaVarenicline Tartrate | 11 | $6,435 |
| Prednisolone Acetate | 96 | $3,014 |
| MoxifloxacinMoxifloxacin Hcl | 121 | $2,654 |
| Loteprednol Etabonate | 12 | $1,513 |
| Pilocarpine Hcl | 14 | $947 |
| Ketorolac Tromethamine | 44 | $726 |
| Acyclovir | 13 | $289 |
| Latanoprost | 21 | $195 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 18 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $190,053 | $60,51964 claims |
| AbbVieRestasis | $1,344 | $19,24117 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $67 | $16,74454 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $23 | $6,43511 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $282 | $1,51312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Bellaire
- Charles WykoffBellaire$1.5M
- Otis WaltonBellaire$311K
- Prethy RaoBellaire$85K
- Hasenin Al-KhersanBellaire$76K
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.